Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLI1 | Q01543 | 5/20 | 1.00 |
| ▸ | EWSR1 | Q01844 | 5/20 | 1.00 |
| ▸ | ERG | P11308 | 1/20 | 1.00 |
| ▸ | ETV1 | P50549 | 1/20 | 1.00 |
| ▸ | MMP2 | P08253 | 5/20 | 0.64 |
| ▸ | MMP9 | P14780 | 5/20 | 0.64 |
| ▸ | MMP8 | P22894 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CBX7 | O95931 | 1/20 | 0.47 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19829782 | 1.00 | FLI1 (1.00) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL19829781 | 1.00 | FLI1 (1.00) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL3486735 | 1.00 | FLI1 (1.00) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL29810794 | 0.91 | FLI1 (0.83) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL17679820 | 0.91 | FLI1 (0.83) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL17669251 | 0.91 | FLI1 (0.83) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL17679823 | 0.91 | FLI1 (0.83) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL15337311 | 0.89 | FLI1 (0.80) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL19419557 | 0.88 | FLI1 (0.78) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL15337268 | 0.88 | FLI1 (0.78) | FLI1EWSR1ERGETV1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731769-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS BY TRIGGERING ANTI-VIRAL RESPONSE | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2026-04-29 | — | — | EP | claimed |
| WO-2024263933-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS BY TRIGGERING ANTI-VIRAL RESPONSE | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2024-12-26 | — | — | WO | claimed |
| CN-118986970-A | Application of small molecular compound YK-4-279 in preparation of hepatitis B treatment drug | 重庆医科大学国际体外诊断研究院 | 2024-11-22 | — | — | CN | claimed |
| CN-118526488-A | Application of inhibitor for inhibiting FLI1 transcription to inhibit kynurenine generation | 湖南灵康医疗科技有限公司 | 2024-08-23 | — | — | CN | claimed |
| US-20240139153-A1 | Inhibition of Endothelial ETS Family Transcription Factors Promotes Flow-Dependent Ocular Vessel Regression | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2024-05-02 | — | — | US | claimed |
| EP-4213838-A2 | INHIBITION OF ENDOTHELIAL ETS FAMILY TRANSCRIPTION FACTORS PROMOTES FLOW-DEPENDENT OCULAR VESSEL REGRESSION | Oklahoma Medical Research Foundation (US) | 2023-07-26 | — | — | EP | claimed |
| US-11679082-B2 | Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-06-20 | — | — | US | claimed |
| US-20220257516-A1 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-08-18 | — | — | US | claimed |
| EP-3996750-A1 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | Oregon Health & Science University (US) | 2022-05-18 | — | — | EP | claimed |
| WO-2022060856-A2 | INHIBITION OF ENDOTHELIAL ETS FAMILY TRANSCRIPTION FACTORS PROMOTES FLOW-DEPENDENT OCULAR VESSEL REGRESSION | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2022-03-24 | — | — | WO | claimed |
| US-20220071906-A1 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-03-10 | — | — | US | claimed |
| CN-114096280-A | Therapeutic constructs for co-delivery of mitotic kinase inhibitors and immune checkpoint inhibitors | 俄勒冈健康与科学大学 | 2022-02-25 | — | — | CN | claimed |
| US-12637720-B2 | Molecular subtyping of small cell lung cancer to predict therapeutic responses | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260124210-A1 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF ANTI-CANCER AGENT(S) AND IMMUNE CHECKPOINT INHIBITOR(S) | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4731769-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS BY TRIGGERING ANTI-VIRAL RESPONSE | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12582658-B2 | Therapeutic constructs for co-delivery of anti-cancer agent(s) and immune checkpoint inhibitor(s) | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| WO-2022060856-A2 | INHIBITION OF ENDOTHELIAL ETS FAMILY TRANSCRIPTION FACTORS PROMOTES FLOW-DEPENDENT OCULAR VESSEL REGRESSION | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220071906-A1 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-03-10 | — | — | US | disclosed |
| CN-114096280-A | Therapeutic constructs for co-delivery of mitotic kinase inhibitors and immune checkpoint inhibitors | 俄勒冈健康与科学大学 | 2022-02-25 | — | — | CN | disclosed |
| CN-114096274-A | Immunotherapeutic constructs and methods of use thereof | 俄勒冈健康与科学大学 | 2022-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139153-A1 | Inhibition of Endothelial ETS Family Transcription Factors Promotes Flow-Dependent Ocular Vessel Regression | ELF3, EDF1, PGF | FLI1 344/4885EWSR1 1114/4885ERG 49/4885 |
| US-12582658-B2 | Therapeutic constructs for co-delivery of anti-cancer agent(s) and immune checkpoint inhibitor(s) | PLK1, BUB1, WEE1 | FLI1 2878/4885EWSR1 1642/4885ERG 2234/4885 |
| US-20260124210-A1 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF ANTI-CANCER AGENT(S) AND IMMUNE CHECKPOINT INHIBITOR(S) | PLK1, BUB1, BUB1B | FLI1 2627/4885EWSR1 1704/4885ERG 2020/4885 |
| US-12637720-B2 | Molecular subtyping of small cell lung cancer to predict therapeutic responses | POU2F1, POU2F2, PARP2 | FLI1 518/4885EWSR1 1000/4885ERG 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.